While the full cCTC model comparing trajectories of biomarkers between HR+ and HER2+ disease did not find any significant association between metastatic site and biomarker status, the full T2CTC model did find a significant baseline effect of Trop2 expression, with a marginally significant difference in slope between receptor statuses after diagnosis with bone metastasis. This evidence concerns the gene ERBB2 and bone metastasis.